Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Healthy Participants 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Solid Tumor, Adult 2Healthy Volunteers 2Breast Neoplasms 2cMET-dysregulated Advanced Solid Tumors 1TP53 Y220C Mutation 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pain 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Healthy Adult Participants 1Healthy 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Chronic Cough 1Carcinoma, Squamous Cell 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Non-small Cell Lung Cancer 1

Interventions

vorasidenib 1repaglinide 1Rosuvastatin Calcium 1Omeprazole 1Midazolam 1Flurbiprofen 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Healthy Adult Participants × Rosuvastatin Calcium × Clear all
NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡